| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/05/2023 | 53.49% | Oppenheimer | $11 → $10 | Maintains | Outperform |
| 09/26/2023 | 22.79% | Citigroup | $10 → $8 | Maintains | Neutral |
| 09/08/2023 | 7.44% | Barclays | $8 → $7 | Downgrades | Equal-Weight → Underweight |
| 08/25/2023 | 22.79% | RBC Capital | $9 → $8 | Downgrades | Outperform → Sector Perform |
| 08/07/2023 | -7.9% | B of A Securities | $10 → $6 | Downgrades | Neutral → Underperform |
| 08/04/2023 | 38.14% | Morgan Stanley | $11 → $9 | Maintains | Equal-Weight |
| 08/04/2023 | 22.79% | Barclays | $12 → $8 | Maintains | Equal-Weight |
| 08/04/2023 | 38.14% | RBC Capital | $14 → $9 | Maintains | Outperform |
| 08/04/2023 | 45.82% | Goldman Sachs | $11 → $9.5 | Maintains | Buy |
| 08/04/2023 | 68.84% | Oppenheimer | $12 → $11 | Maintains | Outperform |
| 08/04/2023 | 22.79% | Wells Fargo | $15 → $8 | Downgrades | Overweight → Equal-Weight |
| 07/05/2023 | 84.19% | Oppenheimer | $11 → $12 | Maintains | Outperform |
| 06/13/2023 | 68.84% | Oppenheimer | → $11 | Initiates Coverage On | → Outperform |
| 05/10/2023 | 68.84% | Goldman Sachs | $12.4 → $11 | Maintains | Buy |
| 05/10/2023 | 68.84% | Morgan Stanley | $12 → $11 | Maintains | Equal-Weight |
| 04/17/2023 | 114.89% | RBC Capital | → $14 | Reiterates | → Outperform |
| 03/10/2023 | 114.89% | RBC Capital | → $14 | Reiterates | → Outperform |
| 03/02/2023 | 130.24% | Wells Fargo | $14 → $15 | Maintains | Overweight |
| 03/02/2023 | 114.89% | RBC Capital | $12 → $14 | Maintains | Outperform |
| 02/06/2023 | 84.19% | Morgan Stanley | $11 → $12 | Downgrades | Overweight → Equal-Weight |
| 01/04/2023 | 68.84% | Morgan Stanley | $13 → $11 | Maintains | Overweight |
| 11/09/2022 | 122.56% | Goldman Sachs | $17 → $14.5 | Maintains | Buy |
| 11/09/2022 | 114.89% | Wells Fargo | $15 → $14 | Maintains | Overweight |
| 11/09/2022 | 84.19% | RBC Capital | $13 → $12 | Maintains | Outperform |
| 11/09/2022 | 99.54% | Morgan Stanley | $14 → $13 | Maintains | Overweight |
| 10/07/2022 | 130.24% | Wells Fargo | $18 → $15 | Maintains | Overweight |
| 09/28/2022 | 99.54% | RBC Capital | $16 → $13 | Maintains | Outperform |
| 09/27/2022 | 114.89% | Morgan Stanley | $15 → $14 | Maintains | Overweight |
| 09/13/2022 | 130.24% | Morgan Stanley | $16 → $15 | Maintains | Overweight |
| 08/10/2022 | 145.59% | Morgan Stanley | $17 → $16 | Maintains | Overweight |
| 08/10/2022 | 145.59% | RBC Capital | $18 → $16 | Maintains | Outperform |
| 07/13/2022 | 206.98% | Wells Fargo | → $20 | Initiates Coverage On | → Overweight |
| 07/01/2022 | 176.29% | RBC Capital | $23 → $18 | Maintains | Outperform |
| 05/26/2022 | 160.94% | Morgan Stanley | $18 → $17 | Maintains | Overweight |
| 05/10/2022 | 176.29% | Morgan Stanley | $19 → $18 | Maintains | Overweight |
| 04/19/2022 | 206.98% | Goldman Sachs | $23 → $20 | Maintains | Buy |
| 03/11/2022 | 191.63% | Morgan Stanley | $20 → $19 | Maintains | Overweight |
| 02/07/2022 | 206.98% | Morgan Stanley | $28 → $20 | Maintains | Overweight |
| 02/03/2022 | 145.59% | Barclays | $25 → $16 | Downgrades | Overweight → Equal-Weight |
| 12/02/2021 | 329.78% | Morgan Stanley | $27 → $28 | Maintains | Overweight |
| 09/30/2021 | 329.78% | Morgan Stanley | $30 → $28 | Maintains | Overweight |
| 07/30/2021 | 360.48% | Morgan Stanley | $32 → $30 | Maintains | Overweight |
| 05/18/2021 | 391.17% | Morgan Stanley | $30 → $32 | Maintains | Overweight |
| 04/30/2021 | 360.48% | Morgan Stanley | $28 → $30 | Maintains | Overweight |
| 03/31/2021 | 360.48% | Jefferies | → $30 | Initiates Coverage On | → Buy |
| 03/08/2021 | 329.78% | Morgan Stanley | → $28 | Upgrades | Equal-Weight → Overweight |
| 02/26/2021 | 329.78% | Morgan Stanley | $30 → $28 | Maintains | Equal-Weight |
What is the target price for Clarivate (CLVT)?
The latest price target for Clarivate (NYSE: CLVT) was reported by Oppenheimer on October 5, 2023. The analyst firm set a price target for $10.00 expecting CLVT to rise to within 12 months (a possible 53.49% upside). 26 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Clarivate (CLVT)?
The latest analyst rating for Clarivate (NYSE: CLVT) was provided by Oppenheimer, and Clarivate maintained their outperform rating.
When is the next analyst rating going to be posted or updated for Clarivate (CLVT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Clarivate, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Clarivate was filed on October 5, 2023 so you should expect the next rating to be made available sometime around October 5, 2024.
Is the Analyst Rating Clarivate (CLVT) correct?
While ratings are subjective and will change, the latest Clarivate (CLVT) rating was a maintained with a price target of $11.00 to $10.00. The current price Clarivate (CLVT) is trading at is $6.52, which is out of the analyst's predicted range.